Michelle E Melisko

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
    Wendy Lorizio
    Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero Street, Suite 322, San Francisco, CA 94143 0320, USA
    Genome Med 3:64. 2011
  2. ncbi request reprint Reactivation of hepatitis C virus after chemotherapy for colon cancer
    M E Melisko
    Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Clin Oncol (R Coll Radiol) 16:204-5. 2004
  3. ncbi request reprint Brain metastases of breast cancer
    Michelle E Melisko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 5:253-68. 2005
  4. doi request reprint Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Neurooncol 88:359-65. 2008
  5. pmc Amelioration of sexual adverse effects in the early breast cancer patient
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 94115, USA
    J Cancer Surviv 4:247-55. 2010
  6. pmc Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer
    Joseph M Letourneau
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, San Francisco, California, USA
    Cancer 118:1933-9. 2012
  7. pmc Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer
    A Jo Chien
    A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, and Mark M Moasser, Helen Diller Family Comprehensive Cancer Center A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, and Mark M Moasser, University of California San Francisco, San Francisco, CA and Kevin M Koch, GlaxoSmithKline, Research Triangle Park, NC
    J Clin Oncol 32:1472-9. 2014
  8. doi request reprint Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer
    A Jo Chien
    Department of Medicine, University of California, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 153:173-81. 2015
  9. doi request reprint New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
    Michelle E Melisko
    Breast Oncology Clinical Trials Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115 1710, USA
    Nat Clin Pract Oncol 6:25-33. 2009
  10. ncbi request reprint Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers
    Michelle E Melisko
    University of California, San Francisco, USA
    Clin Breast Cancer 6:45-54. 2005

Collaborators

Detail Information

Publications16

  1. pmc Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment
    Wendy Lorizio
    Division of General Internal Medicine, Department of Medicine, University of California San Francisco, 1545 Divisadero Street, Suite 322, San Francisco, CA 94143 0320, USA
    Genome Med 3:64. 2011
    ..We evaluated the effect of CYP2D6 testing in clinical practice to determine whether genotype results affected choice of hormone therapy in a prospective cohort study...
  2. ncbi request reprint Reactivation of hepatitis C virus after chemotherapy for colon cancer
    M E Melisko
    Comprehensive Cancer Center, University of California, San Francisco, California 94115, USA
    Clin Oncol (R Coll Radiol) 16:204-5. 2004
    ..We report the clinical course of HCV reactivation in a patient receiving chemotherapy for metastatic colon cancer. We also review other reports showing the significance of HCV infection in patients being treated with chemotherapy...
  3. ncbi request reprint Brain metastases of breast cancer
    Michelle E Melisko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 5:253-68. 2005
    ..New approaches include chemotherapy combinations, biologic therapies and novel drug-delivery strategies...
  4. doi request reprint Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Neurooncol 88:359-65. 2008
    ..As breast cancer patients live longer with control of systemic disease, survival after the diagnosis of brain metastases (BM) also appears to be improving...
  5. pmc Amelioration of sexual adverse effects in the early breast cancer patient
    Michelle E Melisko
    Department of Medicine, University of California San Francisco, 94115, USA
    J Cancer Surviv 4:247-55. 2010
    ....
  6. pmc Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer
    Joseph M Letourneau
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, San Francisco, California, USA
    Cancer 118:1933-9. 2012
    ..The authors sought to describe the age-specific impact of infertility and early menopause after chemotherapy among reproductive age women with cancer...
  7. pmc Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer
    A Jo Chien
    A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, and Mark M Moasser, Helen Diller Family Comprehensive Cancer Center A Jo Chien, Pamela N Munster, Michelle E Melisko, Hope S Rugo, John W Park, Andrei Goga, Glenna Auerback, Elham Khanafshar, Karen Ordovas, and Mark M Moasser, University of California San Francisco, San Francisco, CA and Kevin M Koch, GlaxoSmithKline, Research Triangle Park, NC
    J Clin Oncol 32:1472-9. 2014
    ..In mouse models, such doses are not tolerable in continuous administration, but they are tolerable and highly effective in intermittent dosing. We pursued the clinical translation of this treatment hypothesis...
  8. doi request reprint Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer
    A Jo Chien
    Department of Medicine, University of California, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 153:173-81. 2015
    ..Tamoxifen use in the absence of chemotherapy is not associated with an earlier age onset of menopause in patients with DCIS or invasive breast cancer and is unlikely to significantly accelerate ovarian aging...
  9. doi request reprint New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer
    Michelle E Melisko
    Breast Oncology Clinical Trials Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115 1710, USA
    Nat Clin Pract Oncol 6:25-33. 2009
    ....
  10. ncbi request reprint Patient and physician attitudes toward breast cancer clinical trials: developing interventions based on understanding barriers
    Michelle E Melisko
    University of California, San Francisco, USA
    Clin Breast Cancer 6:45-54. 2005
    ..Also, with increasing patient interest in complementary and alternative medicine (CAM) for cancer, we explored attitudes regarding CAM clinical trials...
  11. pmc A changing perspective: improving access to fertility preservation
    Joseph M Letourneau
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, 94143, USA
    Nat Rev Clin Oncol 8:56-60. 2011
    ..Finally, we present options for fertility preservation, based on the time point at which consultation occurs...
  12. doi request reprint Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial
    Michelle E Melisko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco
    JAMA Oncol . 2016
    ..Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance...
  13. ncbi request reprint Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer
    John W Park
    University of California, San Francisco, San Francisco, CA 94115 1710, USA
    J Clin Oncol 25:3680-7. 2007
    ..We conducted a phase I study to evaluate the safety and immunologic activity of lapuleucel-T in patients with HER-2-overexpressing metastatic breast cancer...
  14. doi request reprint Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer
    Jin Sun Lee
    Division of Hematology Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 2340 Sutter Street, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 154:339-49. 2015
    ..CSFTC detection using a modified CellSearchâ„¢ assay demonstrated high sensitivity in detecting malignant cells in CSF and may be a promising method for diagnosing LM and monitoring LM during treatment. ..
  15. doi request reprint A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Amy Jo Chien
    Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA, 94115, USA
    Breast Cancer Res Treat 155:521-30. 2016
    ..Preclinical studies demonstrate synergy between MK-2206, a selective allosteric Akt-inhibitor, with paclitaxel and trastuzumab. We aimed to evaluate the safety of this combination in patients with HER2+ malignancies...
  16. pmc Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer
    Joseph M Letourneau
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California, USA
    Cancer 118:1710-7. 2012
    ..The post-treatment quality of life (QOL) impacts of receiving precancer-treatment infertility counseling and of pursuing fertility preservation have not been described in large-scale studies of reproductive age women with cancer...